Join
Live feed
·
PRReleasevia Quantisnow
Aprea Therapeutics Inc. logo

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

ByQuantisnow·Wall Street's wire, on your screen.
APRE· Aprea Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APRE (Aprea Therapeutics Inc.) and more on Quantisnow.